Blood News and Research

RSS

New mechanism explains why anti-tumor activity of specific immune suppressed during tumor growth

The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response.

12 Dec 2013

Tohoku University, Thomson Reuters team up to restore Tohoku’s medical system

The Intellectual Property & Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced a collaboration with Tohoku University Tohoku Medical Megabank Organization (ToMMo) to help restore Tohoku's medical system to its pre-earthquake state and help its medical community further develop its research efforts.

12 Dec 2013

Inflating balloon inside artery after stent placement increases patients' risk of serious complications

Johns Hopkins surgeons say skipping one commonly taken step during a routine procedure to insert a wire mesh stent into a partially blocked carotid artery appears to prevent patients from developing dangerously low blood pressure, an extremely slow heart rate or even a stroke or heart attack.

12 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

HCV antiviral therapy also improves diabetes outcomes

Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus improves kidney and cardiovascular outcomes for patients with diabetes. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that incidences of kidney disease, stroke, and heart attack were lower in patients treated with pegylated interferon and ribavirin compared to HCV patients not treated with antivirals or diabetic patients not infected with the virus.

12 Dec 2013

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment.

12 Dec 2013

Two tumor-suppressing genes could play vital role in controlling obesity, cancer, diabetes

The function of two tumor-suppressing genes could play a vital role in helping to control obesity and other diseases such as diabetes, heart disease and cancer, according to researchers in Temple University's Sbarro Institute for Cancer Research and Molecular Medicine.

12 Dec 2013

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium.

12 Dec 2013

New guidelines developed to manage heart failure in children with undiagnosed heart disease

Heart failure in children is an important cause of childhood health problems and death. The Children's Heart Failure Study Group of the Canadian Cardiovascular Society, in collaboration with the Canadian Pediatric Cardiology Association, has developed new guidelines to assist practitioners in primary care and emergency departments to recognize and successfully manage heart failure in children with undiagnosed heart disease and symptoms of possible heart failure. The guidelines are published in the December issue of the Canadian Journal of Cardiology.

12 Dec 2013

Researchers awarded $25 million NIH grant to study critical limb ischemia treatment

A team of researchers from Brigham and Women's Hospital, Boston Medical Center and Massachusetts General Hospital has been awarded $25 million by the National Institutes of Health to conduct a four-year, randomized clinical trial-the BEST-CLI Trial (Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia). The trial will compare traditional bypass surgery with the less invasive alternative of endovascular treatment for patients with critical limb ischemia.

11 Dec 2013

FDA advisory committee votes in favor of WATCHMAN Left Atrial Appendage Closure device

The U.S. Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the WATCHMAN Left Atrial Appendage Closure device outweigh the risks.

11 Dec 2013

Researchers find decreased energy metabolism in heart cells as significant independent risk factor

Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which ones have a better prognosis. Their study is one of the first to show that energy metabolism within the heart, measured using a noninvasive magnetic resonance imaging test, is a significant predictor of clinical outcomes, independent of a patient's symptoms or the strength of the heart's ability to pump blood, known as the ejection fraction.

11 Dec 2013

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million.

11 Dec 2013

SynCardia Systems sets new record with 150th implant of temporary Total Artificial Heart

SynCardia Systems, Inc. continues to set records with the implantation of the year's 150th SynCardia temporary Total Artificial Heart on Nov. 26, 2013.

11 Dec 2013

Prana Biotechnology provides update on IMAGINE PBT2 trial for Alzheimer’s disease

Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today provided an update of its IMAGINE Alzheimer’s Disease Extension trial.

11 Dec 2013

Detectable blood viral load increases prevalence of heart disease

HIV causes structural heart disease according to research presented at EuroEcho-Imaging 2013 by Dr Nieves Montoro from Madrid, Spain. The findings support the introduction of cardiovascular screening in all HIV patients, particularly those with a positive blood viral load.

11 Dec 2013

State highlights: Health care price data and transparency in N.Y. and Calif.; states shift tobacco settlement funds away from prevention

Just how expensive is your hospital? In New York, the answer may lie in a trove of hospital cost data newly posted online by the State Health Department. As part of an effort to make health care pricing more transparent, the state is naming hospitals and listing their median charges and costs for 1,400 conditions and procedures from 2009 to 2011.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients enrolled in the phase 3 Hokusai-VTE study.

11 Dec 2013

Researchers personalizing cancer treatments for young patients

The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.

11 Dec 2013

Blood News and Research

New mechanism explains why anti-tumor activity of specific immune suppressed during tumor growth

Tohoku University, Thomson Reuters team up to restore Tohoku’s medical system

Inflating balloon inside artery after stent placement increases patients' risk of serious complications

Emergent BioSolutions enters into definitive agreement to acquire Cangene

HCV antiviral therapy also improves diabetes outcomes

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

Two tumor-suppressing genes could play vital role in controlling obesity, cancer, diabetes

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

New guidelines developed to manage heart failure in children with undiagnosed heart disease

Researchers awarded $25 million NIH grant to study critical limb ischemia treatment

FDA advisory committee votes in favor of WATCHMAN Left Atrial Appendage Closure device

Researchers find decreased energy metabolism in heart cells as significant independent risk factor

Crealta to acquire all assets of Savient Pharmaceuticals

SynCardia Systems sets new record with 150th implant of temporary Total Artificial Heart

Prana Biotechnology provides update on IMAGINE PBT2 trial for Alzheimer’s disease

Detectable blood viral load increases prevalence of heart disease

State highlights: Health care price data and transparency in N.Y. and Calif.; states shift tobacco settlement funds away from prevention

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Researchers personalizing cancer treatments for young patients

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News